These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20643458)

  • 1. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
    Alibhai SM; Duong-Hua M; Cheung AM; Sutradhar R; Warde P; Fleshner NE; Paszat L
    J Urol; 2010 Sep; 184(3):918-23. PubMed ID: 20643458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
    Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
    Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture risk following bilateral orchiectomy.
    Melton LJ; Alothman KI; Khosla S; Achenbach SJ; Oberg AL; Zincke H
    J Urol; 2003 May; 169(5):1747-50. PubMed ID: 12686824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for low trauma fractures in men with prostate cancer.
    Ahlborg HG; Nguyen ND; Center JR; Eisman JA; Nguyen TV
    Bone; 2008 Sep; 43(3):556-60. PubMed ID: 18585119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
    Smith MR; Lee WC; Brandman J; Wang Q; Botteman M; Pashos CL
    J Clin Oncol; 2005 Nov; 23(31):7897-903. PubMed ID: 16258089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
    J Urol; 2013 Jan; 189(1 Suppl):S45-50. PubMed ID: 23234631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.